NasdaqGS:NTRABiotechs
Krystal Biotech Stock And 2 Biotech Names With Pipeline Catalysts
The latest headlines around AstraZeneca, from its £207b valuation to its multibillion dollar R&D and expansion plans, show how a single company’s choices on investment, geography, and pipeline risk can ripple across the wider pharmaceuticals and biotechnology sector. For investors, this news creates both potential opportunity and fresh questions about concentration in China, future drug exclusivity, and the impact of trial setbacks. This article looks at 3 large cap stocks from our...